To address this unmet medical need, PHOENIX will conduct the first international Phase I/II clinical trial evaluating ibrilatazar, an innovative anticancer drug with the potential to provide a safer therapeutic approach by selectively targeting tumour cells while reducing damage to healthy tissues.
Beyond the clinical trial, the project integrates biomarker discovery, liquid biopsy technologies and personalised medicine to better predict treatment response and support more precise clinical decision-making. By bringing together leading clinical, scientific and communication partners, PHOENIX aims to generate the evidence needed to improve survival, reduce treatment-related toxicity and contribute to a new generation of personalised therapies for children with cancer.
PHOENIX is a Horizon Europe Cancer Mission project dedicated to improving treatment options for children and adolescents with relapsed or treatment-resistant solid tumours. While survival rates for childhood cancer have increased considerably over recent decades, patients with high-risk cancers continue to face limited therapeutic options, and current treatments often result in severe long-term side effects that affect their quality of life well into adulthood.
To address this unmet medical need, PHOENIX will conduct the first international Phase I/II clinical trial evaluating ibrilatazar, an innovative anticancer drug with the potential to provide a safer therapeutic approach by selectively targeting tumour cells while reducing damage to healthy tissues.
Beyond the clinical trial, the project integrates biomarker discovery, liquid biopsy technologies and personalised medicine to better predict treatment response and support more precise clinical decision-making. By bringing together leading clinical, scientific and communication partners, PHOENIX aims to generate the evidence needed to improve survival, reduce treatment-related toxicity and contribute to a new generation of personalised therapies for children with cancer.
PHOENIX is coordinated by the Vall d'Hebron Research Institute (VHIR) and brings together 13 organisations from 7 European countries, combining expertise in paediatric oncology, clinical research, pharmaceutical development, personalised medicine, communication and patient engagement.
The consortium includes leading hospitals, research institutes, universities, industry and specialised organisations working together to accelerate the development of safer and more effective treatments for children with high-risk cancers.